PeproMene Bio, Inc. Announced Complete Response of The First P... - 21 December 2022 12:00

IRVINE, Calif., Dec. 21, 2022 /PRNewswire-AsiaNet/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) cl...

  Huaiyin in Jinan, Shandong, Intent on Transforming into China'... - 20 December 2022 23:04

JINAN, China, Dec. 20, 2022 /Xinhua-AsiaNet/-- According to information released on December 13 by the People's Government of Huaiyin District, Huaiyin will expend all necessary effort on building a new medical science city comprising an international smart medical city, a green health demonst...

  Carrick Therapeutics and The Menarini Group Announce Clinical ... - 20 December 2022 02:24

DUBLIN and FLORENCE, Italy, December 19, 2022 /PRNewswire-AsiaNet/-- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a ...

  Health and Hydrogen launches one of the first medical-grade Mo... - 19 December 2022 23:28

GURGAON, India, Dec. 19, 2022 /PRNewswire-AsiaNet/ -- Molecular Hydrogen Inhalation therapy is now extensively used for its many health benefits, such as reducing inflammation, improving cellular function, and protecting against oxidative stress. Health And Hydrogen [ https://healthandhydrogen.co...

  CES 2023:OMRON Healthcare Introducing Initiatives to Advance I... - 16 December 2022 19:00

KYOTO, Japan, Dec. 16, 2022 /Kyodo JBN-Asianet/ -- OMRON Healthcare Co., Ltd. (hereinafter the Company) will exhibit at CES 2023 (*), the world's largest consumer tech show taking place in Las Vegas from Thursday, January 5, through Sunday, January 8. At the show, the Company will showcase the inn...

  Novavax Announces Pricing of $65 Million Public Offering of Co... - 16 December 2022 17:23

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire-AsiaNet/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of ...

  Novavax Announces Pricing of $150 Million Offering of Converti... - 16 December 2022 16:56

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire-Asianet/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of it...

  Novavax Announces Proposed Offering of $125 Million of Convert... - 16 December 2022 02:00

GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire-AsiaNet/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertib...

  Pharming announces positive interim analysis data from open-la... - 15 December 2022 17:00

LEIDEN, Netherlands, Dec. 15, 2022 /PRNewswire-AsiaNet/ -- V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated t...

  Hovione and GEA announce a strategic collaboration to advance ... - 15 December 2022 00:58

LISBON, Portugal, Dec. 14, 2022, /PRNewswire-AsiaNet/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s dev...